基于Oncomine和TCGA数据挖掘分析MTERF2在胰腺癌中的表达及临床意义  

Data-Mining from Oncomine Database and TCGA for MTERF2 Expression in Human Pancreatic Cancer

作　　者：王唯斯 梅雯 孙美涛 李彬 张态 张若鹏 熊伟 WANG Wei-Si;MEI Wen;SUN Mei-Tao;LI Bin;ZHANG Tai;ZHANG Ruo-Peng;XIONG Wei(College of Basic Medical Sciences,Dali University,Dali 671000,China;College of Public Health,Dali University,Dali 671000,China;First Affiliated Hospital,Dali University,Dali 671000,China)

机构地区：[1]大理大学基础医学院,云南大理671000 [2]大理大学公共卫生学院,云南大理671000 [3]大理大学第一附属医院,云南大理671000

出　　处：《生物技术通讯》2019年第2期163-169,共7页Letters in Biotechnology

基　　金：国家自然科学基金(81560458;31601155);云南省中青年学术和技术带头人后备人才项目(2017HB077);云南省教育厅科学研究基金指导性项目(2016ZDX01;2016ZDX05);大理大学博士科研启动基金(BSKY2012018);大理大学大学生创新创业计划(S-CXCY-2017-8)

摘　　要：目的:探究人线粒体转录终止因子2(MTERF2)在胰腺癌中的表达及临床意义。方法:检索Oncomine数据库中的MTERF2信息,对其在胰腺癌组织和正常胰腺组织中的表达进行荟萃分析;从美国癌症基因组图谱(TCGA)中下载胰腺癌数据集MTERF2 RNA Seq V2数据及临床病理资料;利用R 2.15.3软件分析MTERF2表达量与临床病理参数的相关性及预后;利用Kaplan-Meier生存函数分析MTERF2表达量和胰腺癌患者预后的关联。结果:Oncomine数据库中共收集了586个不同类型的研究结果,其中关于MTERF2表达有统计学差异的研究有58个,MTERF2表达增高的研究有26个,表达减低的研究有32个。共有9项研究涉及MTERF2在胰腺癌组织和正常组织中的表达,包括226例临床样本,与对照组相比,MTERF2在胰腺癌中低表达(P=7.34×10-6)。TCGA胰腺癌数据集中共收集179例具有临床病理参数的病例及其对应的MTERF2 mRNA表达量。剔除病理参数不详或不完整的病例,利用R 2.15.3软件分析发现,MTERF2 mRNA表达量与胰腺癌患者T分期、M分期、癌症类型及原发部位存在显著相关(均P<0.05),而与患者的年龄、性别、N分期、AJCC病理分期、等级、组织学类型及饮酒史无显著相关(均P>0.05)。Kaplan-Meier生存分析发现,胰腺癌患者MTERF2的表达水平与总生存率(OS)无显著相关性(P>0.05),而与无病生存率(DFS)显著相关(P<0.001)。结论:Oncomine和TCGA数据挖掘显示,人MTERF2在胰腺癌组织中低表达,且MTERF2表达量与胰腺癌患者总生存率无显著相关性,与无病生存率有显著相关性。Objective:To explore the expression of human mitochondrial transcription termination factor 2(MTERF2)and its clinic significance in pancreatic cancer.Methods:Data about human MTERF2 were retrieved from the Oncomine database and the role of MTERF2 in pancreatic cancer was analyzed.The expression of MTERF2 and clinical information in pancreatic cancer patients were downloaded from The Cancer Genome Atlas(TCGA)database by R 2.15.3 software.Then the relationship between the expression of MTERF2 mRNA and clinicopathological characteristics,and the prognostic value of MTERF2 expression were analyzed.Results:Totally,586 studies of different types relevant to the expression of MTERF2 were identified in the Oncomine database.The MTERF2 expression was statistically significant in 58 of the studies,overexpressed in 26 studies and underexpressed in 32 studies.A total of 9 studies were involved MTERF2 pancreatic cancer tissues and normal tissues,including a total of 226 samples.Overall,MTERF2 expression in pancreatic cancer tissues were lower than that in normal tissues.TCGA database was used to collect 179 cases with clinical pathological parameters and their corresponding MTERF2 expression levels.After the incomplete cases and those with no detailed pathological parameters were excluded,it was found that the expression level of MTERF2 mRNA was significantly correlated with the T stage,M stage,type of cancer,and primary site in patients with pancreatic by cancer R 2.15.3 software analysis.There was no significant correlation between age,sex,N stage,AJCC pathological stage,grade,histologi?cal type and drinking history.Kaplan-Meier survival analysis showed that there was no significant correlation between MTERF2 expression level and total survival rate in patients with pancreatic cancer,but a significant correlation with disease-free survival.Conclusion:Through the in-depth data mining of the TCGA cancer database and the Oncomine gene chip database,it is suggested that MTERF2 is lower expressed in pancreatic cancer,there was n

关 键 词：线粒体转录终止因子2(MTERF2) 胰腺癌 Oncomine数据库 癌症基因组图谱(TCGA) 数据挖掘 

分 类 号：Q811.4[生物学—生物工程] R735.9[医药卫生—肿瘤]